How many insider trades does FilingIQ track for ACRS?

FilingIQ tracks 691 Form 4 insider transactions for ACRS (Aclaris Therapeutics, Inc.), covering filings from Oct 6, 2015 onwards. 7 of those were filed in the last 90 days.

Are ACRS insiders net buyers or net sellers?

Across the full Form 4 history for ACRS, 66 transactions (10%) were open-market purchases and 111 (16%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ACRS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ACRS in?

Aclaris Therapeutics, Inc. (ACRS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $349.96M.

ACRS insider trading

NasdaqGS Healthcare

Aclaris Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

691

Last 90 days

Buys / sells

10% / 16%

Market cap

$349.96M

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Company website: www.aclaristx.com

ACRS insider activity at a glance

FilingIQ has scored 691 insider transactions for ACRS since Oct 6, 2015. The most recent filing in our index is dated May 1, 2026.

Across the full history, 66 open-market purchases and 111 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ACRS insider trades is 52.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ACRS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding ACRS

VR Adviser, LLC

$71.88M · 12.1% of AUM

Samsara BioCapital, LLC

$5.63M · 1.2% of AUM

Frequently asked

How many insider trades does FilingIQ track for ACRS?: FilingIQ tracks 691 Form 4 insider transactions for ACRS (Aclaris Therapeutics, Inc.), covering filings from Oct 6, 2015 onwards. 7 of those were filed in the last 90 days.
Are ACRS insiders net buyers or net sellers?: Across the full Form 4 history for ACRS, 66 transactions (10%) were open-market purchases and 111 (16%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ACRS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ACRS in?: Aclaris Therapeutics, Inc. (ACRS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $349.96M.

Methodology & sources

Every ACRS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.